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Abstract
Despite the increasing prevalence for its diagnosis in children, there are no 
clinical biomarkers of autism spectrum disorders (ASD). Herein a research jour-
ney is described that began by seeking evidence for the opioid excess theory of 
autism using mass spectrometry methods to screen human urine specimens and 
has evolved into the discovery of promising murine fecal biomarkers for ASD. Our 
results are consistent with an emerging body of evidence that shows that intestinal 
microflora from ASD subjects can be distinguished from controls, suggesting that 
metabolite differences due to the action of intestinal microbes may provide a means 
to identify ASD biomarkers.
Keywords: autism, biomarkers, stercobilin, mass spectrometry, metabolomics, 
microbiome
1. Introduction
Autism spectrum disorders (ASD) represent a group of neurobehavioral disor-
ders first reported by Dr. Leo Kanner [1] which are characterized by impairments in 
social interactions, deficits in communications skills, repetitive behaviors, and other 
stereotypical behavioral patterns [2]. High rates of diagnosis in the United States 
(up to 1 in 59 children) [3] exemplify the seriousness of ASD as a medical concern. 
There is great interest in identifying potential ASD biomarkers, as the evidence 
indicates that early diagnosis and intervention leads to improved long-term out-
comes for individuals with ASD [4, 5]. While considerable effort has been dedicated 
toward discovering potential genetic factors associated with ASD, it is becoming 
increasingly clear that genetic factors alone are insufficient to explain overall ASD 
etiology [6]. Combined, these factors have inhibited the development of a grand 
unified theory (GUT) for autism [7] (note: the irony that gut microbiota may be an 
important factor contributing to a GUT of ASD is not lost upon the authors).
While a GUT for ASD may be unrealistic because of heterogeneity in causation 
and severity, increasing attention has been devoted toward identifying potential 
metabolic molecular markers of ASD. One approach has been to consider condi-
tions that are comorbid with ASD, in particular, gastrointestinal distress, which is a 
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condition observed in a high percentage of persons with ASD [8–10]. Interestingly, 
the homeostasis of the central nervous system (CNS) is regulated by the gut 
microbiome [11, 12], and furthermore the microbiome is known to have effects in 
neuropsychiatric disorders [13, 14]. Therefore, the effects of the microbiome on the 
gut-brain axis are a potentially promising source for metabolic biomarker discovery 
for ASD.
In this chapter, we will cover our combined efforts to discover potential ASD 
biomarkers. While we initially explored the possibility that peptides consistent 
with the opioid excess theory of ASD [15] may possess diagnostic value, our search 
took a new direction during the course of research. Our results are discussed within 
the context of our results alongside other research that shows distinctions in the 
microbiota of subjects with ASD vs. controls.
2. The opioid excess theory of autism
Anecdotally, two of the authors of this chapter had observed substantial behav-
ioral improvements in family members who had been diagnosed with childhood 
autism or were exhibiting symptoms of ASD when their diets were altered to avoid 
milk (casein) and/or wheat (gluten), known now as the gluten-free casein-free 
(GFCF) diet [16–18]. Therefore, our journey delving into the etiology of ASD 
initially involved an exploration into the idea of increased intestinal permeability 
[19], also referred to as the “leaky gut syndrome.” This syndrome describes the pas-
sage of potentially bioactive peptides, created from the incomplete breakdown of 
the proteins through the intestinal membrane, into the blood stream and ultimately 
into the brain through the blood-brain barrier (BBB) [20–23]. The combined work 
of Panksepp [15], Shattock [17, 18, 24, 25], Waring [26], Gardner [27], and Reichelt 
[28] caused us to pursue this area of research. Now termed the opioid excess theory, 
this invaluable research from the 1990s and early 2000s explains how some of the 
incompletely metabolized protein pieces are described and compared to endog-
enous opioids, β-endorphins. An outstanding account of the opioid excess theory 
has been described and is highly recommended [29].
3. Transition from the opioid excess theory to potential biomarkers
Our research into ASD biomarkers began by testing the biological effects of admin-
istration of gluten exorphins (GEs) to rodents and by developing methodology to 
detect opioid peptides in biological fluids. Our work was inspired along two avenues. 
The first inspiration was derived from the results of Fukudome et al. who showed that 
in animal models, GE-B5 stimulated glucose-induced insulin release after intragastric 
administration [30]. The second inspiration was derived from the intriguing results of 
the Reichelt group [28], who had demonstrated that dietary intervention to eliminate 
casein and gluten from the diet in individuals with ASD led to improvements in the 
use of social, cognitive, and communicative skills over a period of 4 years.
The Sassari, Italy, experiments were performed to test whether GEs could 
elicit biological activity in rats. Intracerebroventricular (ICV)-injection of gluten 
exorphin B5 into rats stimulated the release of prolactin through activation of 
opioid receptors [31, 32]. Subsequently, efforts to determine the site of action 
of GE-B5 on prolactin secretion were conducted by pretreating male rats with 
naloxone methobromide (NMB), an opioid antagonist that does not cross the 
BBB [33]; NMB preadministration completely abolished the prolactin response. 
These results indicated that GE-B5 stimulates prolactin secretion through opioid 
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receptors located outside the BBB. Since opioid peptides do not exert their effect on 
prolactin secretion directly, but via a reduced dopaminergic response, these data 
suggested that GE-B5 modifies brain neurotransmitter release without crossing the 
BBB. These results clearly demonstrated that GE-B5 could elicit opioid activity in 
rats. Interestingly, GE-B4, whose structure (Tyr-Gly-Gly-Trp) is identical to that 
of the NH2-terminal sequence of GE-B5, did not elicit such activity, thus suggest-
ing that the presence of the carboxyl-terminal leucine in GE-B5 is essential for its 
action on prolactin secretion [34].
In a series of papers published between our groups at Sassari and Buffalo, 
we developed approaches to detect GEs in biological fluids using liquid chroma-
tography-mass spectrometry (LC-MS) methods. First, we used LC-MS to detect 
GE-A5 in sheep cerebrospinal fluid (CSF) [35]. Next, using a slightly different 
protocol, we developed LC-MS for the detection of GE-B5 in CSF and recognized 
that stability was a significant issue; in the absence of protease inhibitors, GE-B5 
degraded more than 50% within 600 min after collection [36]. Thus, when meth-
ods were developed for the detection of GEs in human blood plasma, aprotinin, a 
protease inhibitor, was added to plasma samples from patients with celiac disease 
(CD), a genetic autoimmune disease which induces inflammation to patients’ small 
intestine by their ingestion of gluten. CD patients consumed a pizza made from 
wheat gluten, and their blood was collected at intervals over a 120 min period. 
Using liquid chromatography-tandem mass spectrometry (LC-MS/MS), GE-B4 
and GE-B5 were detected in three of four patients with CD, the first time GEs were 
detected in human blood [37]. An LC-MS/MS spectrum of GE-B5 in blood plasma 
collected from a CD patient 90 min after consumption of pizza containing wheat 
gluten flour is shown in Figure 1. However, GE-B4 and GE-B5 were detected in the 
blood plasma of two of the four patients before consuming the pizza, indicating 
another potential dietary source for the GEs.
Although we had established that GEs were detectable in human blood, their 
rapid degradation in the absence of protease inhibitors led us to become skepti-
cal that GEs would contribute to the opioid excess theory of ASD in a substantive 
way, especially after the report that indicated no significant differences in the 
high-performance liquid chromatography (HPLC) urinary profiles of the children 
with ASD and controls and no detection of GEs in the urine specimens by matrix-
assisted laser desorption/ionization (MALDI) mass spectrometry [38]. Urine had 
shown some promise as a specimen that might harbor biomarkers of diagnostic 
value for ASD [20, 39]. In our own research, serendipity had a hand yet to play, and 
it led to a new viewpoint. GE-B5, one of the target exorphins, produces a [M+H]+ 
ion at m/z 595, with the distinct fragmentation pattern as shown in Figure 1. We had 
Figure 1. 
LC-MS/MS of GE-B5 detected in a sample of human blood plasma taken from a CD patient 90 min after 
consumption of wheat gluten flour pizza, from [37].
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begun using LC-MS/MS to screen for GEs, and other potential opiate peptides, in 
urine. Using specimens from urines collected and reported in [38], we observed by 
LC-MS/MS a significant difference in the abundance of a species with m/z 595 in the 
urine specimens between ASD and controls.
As shown in Figure 2, the LC chromatograms of (A) control and (B) ASD 
urines show a remarkable difference in abundance for this species which elutes at 
~12.9 min; typical depletion in ASD urines was 67% vs. the controls (in Figure 2B 
depletion is a factor of 68). The MS/MS of this species, codenamed “595A” at the 
time, is shown in Figure 2C. Clearly, the fragmentation pattern of 595A does not 
correspond to that of GE-B5 shown in Figure 1 and is dominated by the formation 
of two product ions at m/z 470 and m/z 345, respectively. While we did not know 
the identity of 595A initially, intuition about fragmentation behavior of small 
molecules led us to suspect a particularly stable molecule, perhaps of the porphyrin 
family. The emergence of the Human Metabolome Database (HMDB) in 2007 [40] 
allowed us to search for possible metabolites, and we obtained one hit that satisfied 
the m/z of 595A and porphyrin metabolic pathways—l-stercobilin, C33H46N4O6, 
a metabolite found in mammalian waste products. Subsequently, we purchased 
stercobilin hydrochloride from Frontier Scientific and performed nanoelectrospray 
ionization (nanoESI) and MS/MS on stercobilin hydrochloride and obtained the 
same fragmentation pattern [41], and we have established this identity in a number 
of publications [42–45]. We had thus identified 595A as l-stercobilin as a potential 
biomarker of ASD in human urine. However, methods of performing reliable 
Figure 2. 
Chromatogram of (A) control urine extract and (B) ASD urine extract. (C) MS/MS of the peak at 12.9 min 
in the ASD urine extract, with a precursor ion mass of m/z 595.
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quantification were needed in order to validate whether this was the case; unfortu-
nately, isotopically labeled standards of stercobilin are not commercially available. 
Thus, we embarked on approaches to synthesize a suitable label for stercobilin that 
could be used as an internal standard for mass spectrometry analysis.
4. Strategies for producing tetrapyrrole standards
4.1 Methyl esterification of bilins
In order to test whether stercobilin (or any other tetrapyrrole bilin) might be use-
ful as a potential ASD biomarker, it would be necessary to have a reliable standard for 
quantitative purposes. Our first approach to develop a standard for the bilins was to 
perform methyl esterification [42]. To achieve methyl esterification of bilins, metha-
nolic HCl was first prepared by the combination of 160 μL of acetyl chloride with 
1 mL of anhydrous methanol dropwise slowly. Next, 10 μg of the bilin was dissolved 
in 500 μL of the methanolic HCl and reacted at room temperature for 2 h. This led to 
efficient (>90%), but incomplete, derivatization of stercobilin at its carboxyl groups 
to the dimethylester; MS/MS using collision-induced dissociation (CID) with argon 
gas confirmed that derivatization occurs at each carboxyl group, and although most 
of the bilins were converted to the dimethylester form, a small amount of the mono-
methyl ester was also produced. Furthermore, the dimethylesters were found to have 
high solubility in 50/50 methanol/water; this was found to be problematic for long-
term stability, as the level of esterification would decrease over storage time at 4°C.
4.2 18O labeling of bilins
In another attempt to quantitate stercobilin, an isotopologue standard was 
created based off of the work by Bergmann et al. [46]. Isotopologues are often ideal 
internal standards for quantitation using mass spectrometry because the isotopo-
logue is itself chemically similar to the analyte of interest but is shifted in mass due 
to the incorporation of another isotope. In the structure of stercobilin, the four oxy-
gens within the carboxylic acid groups on the inner pyrroles are labile and able to be 
exchanged with the oxygen atoms of H2
18O (as can be seen in red in Figure 3). The 
reaction works under an acidic environment utilizing trifluoroacetic acid (TFA) as 
a proton donor to aid in the protonation of the carbonyl oxygen for the nucleophilic 
substitution reaction. Currently, we have scaled up our original procedure [47] by 
using ca. 5 × 10−6 mol of stercobilin mixed with 10 μL 5% (v/v) TFA and 95 μL of 
H2
18O in an LC autosampler vial with screw cap lid. The vial is placed in an incuba-
tor at 70°C for 8 h [43]. Following the reaction, the sample is dried down under air 
and reconstituted in 100 mL of 20:80 (v/v) ACN/H2O.
Figure 3. 
The structure of stercobilin with the labile oxygen sites highlighted in red.
Autism Spectrum Disorders - Advances at the End of the Second Decade of the 21st Century
6
To improve upon our previous 18O-stercobilin isotopologue yield, the reaction 
was conducted at a higher temperature [47] than what was reported by Bergmann 
et al. [46]. To further push the reaction toward full labeling, the reaction is carried 
out a second time under the same initial conditions except for allowing it to react 
for 22 h instead of 8. With this a labeling efficiency of 72.1 ± 0.3% was observed 
with minimal original stercobilin left in the reaction (Table 1). The results of this 
experiment have allowed for the quantitation of stercobilin within fecal samples.
4.3 Deuterated stercobilin
Next, we synthesized a more stable isotopologue of stercobilin through the use 
of deuterium-carbon bonds, which were achieved by the incorporation of deute-
rium across several of the carbon-carbon double bonds of bilirubin as described 
by Putzbach et al. [48]. This protocol incorporated deuterium atoms into bilirubin 
affording stercobilin with a mass increase of more than 12 atomic mass units. The 
conversion of bilirubin to stercobilin was previously reported (Figure 4) [49]. 
m/z peak (18On) % labeling
595 (18O0) 0.16 ± 0.04
597 (18O1) 7.2 ± 0.9
599 (18O2) 25.6 ± 0.8
601 (18O3) 38.6 ± 0.7
603 (18O4) 28.5 ± 0.5
Table 1. 
Corresponding m/z peaks from labeled stercobilin with the percentage of labeling of each peak denoted.
Figure 4. 
Step (1) involves the reduction of bilirubin into stercobilinogen. Step (2) involves partial oxidation of 
stercobilinogen into stercobilin (3), our desired product.
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This method allowed us to reduce the six non-pyrrole C〓C double bonds with 
hydrogen gas (control reaction) or with deuterium gas (isotopologue) producing 
stercobilinogen and labeled stercobilinogen, respectively [44, 50]. For the deuterated 
isotopologue, bilirubin (200 mg) was combined with 25 mL deuterated glacial acetic 
acid (CD3COOD) and 200 mg of palladium on carbon, and deuteration was allowed to 
proceed for 1.5 h at 65°C to produce stercobilinogen. Stercobilinogen is subsequently 
aerated in the presence of copper sulfate, resulting in the final product, stercobilin. 
Combined nuclear magnetic resonance (NMR) and MS/MS analysis indicated 
 incorporation of deuterium at all 12 sites, with no evidence of unreacted bilirubin.
5. Biomarker validation: connection to the microbiome
Utilizing the 18O isotopologue standard, the amount of stercobilin could be 
quantified within the fecal samples of a murine model of ASD. In the described 
study, a population of mice with Timothy Syndrome (TS) was utilized; these mice 
have been previously described as exhibiting autistic behaviors. In particular, the 
mice used herein had a more severe case of TS, TS2-NEO, caused by a missense 
mutation in exon 8 at G406R in tandem with a flipped neomycin cassette, allowing 
for the mice to survive to adulthood [51]. Fourteen pairs of mice that were age- and 
gender-matched were utilized in this study.
Response factor calculations were first completed in order to quantify the amount 
of labeled stercobilin in the fecal samples as well as account for the amount of unla-
beled stercobilin that would be present in the sample from the isotopologue standard. 
Calculations of the concentration of stercobilin were determined utilizing the m/z 601 
peak from the labeled stock. Concentrations were then normalized per gram of fecal 
material. From these calculations, box and whisker plots were created and are shown 
in Figure 5 for both stercobilin and its precursor, stercobilinogen. An unpaired t-test 
was utilized to determine p-values and to establish whether the populations’ mean 
bilin levels were statistically significantly different, or not, from each other.
When calculating the average moles of stercobilin utilizing the peak area of the 
m/z of 601 of WT and TS2-NEO populations, values of 1.84 × 10−8 ± 7.1 × 10−9 and 
9.59 × 10−9 ± 4.1 × 10−9 mol/g feces were found for the two populations, respec-
tively. These values show a depletion of ca. 48% in stercobilin levels of TS2-NEO 
mice (p ≤ 0.001). In comparison, calculating the average moles of stercobilinogen 
utilizing the peak area of the m/z of 601 of WT and TS2-NEO populations, values 
of 1.13 × 10−8 ± 1.1 × 10−8 and 5.55 × 10−9 ± 3.7 × 10−9 mol/g feces were found for 
the two populations, respectively. These values showed a depletion of 51% in 
Figure 5. 
A comparison of the average concentration of both stercobilin and stercobilinogen found in wild type (WT) as 
opposed to mice with TS2-NEO per gram of fecal material. The p-values calculated from the unpaired t-test 
are shown in the upper right-hand corner of the box and whisker plots.
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stercobilinogen levels of TS2-NEO mice (p = 0.07). A larger sample set will be nec-
essary to determine the significance of depletion in stercobilinogen. Furthermore, 
the p-values determined were improved upon since our last report with a study of 
nine pairs of mice [43].
The depletion of stercobilin in the ASD model of mice relative to controls at 
a greater than 99.9% confidence level suggests that stercobilin depletion in fecal 
material may have potential value as a biomarker for ASD in humans. Although less 
statistically significant, stercobilinogen, the metabolic precursor to stercobilin, is 
also depleted in fecal samples. The observation of these depletions suggests that 
there may be interference in the metabolic pathway that allows for the differences. 
As shown in Figure 6, stercobilin and stercobilinogen are products of heme catabo-
lism. As bilirubin glucuronides enter the intestines, the action of enzyme systems 
by anaerobic bacterial flora converts the glucuronides to mesobilirubinogen, which 
is further converted to stercobilinogen.
Our results are also intriguing in the context of a discovery decades ago by 
Gustafsson and Lanke in which they observed no bilins present in the feces or urine 
of germfree rats [52]. Once the germfree animals were exposed to fecal matter 
from control animals, they too began to produce bilins to the same extent as the 
controls (when both groups were given identical diets). Moreover, they observed 
that the negative urobilin test (note: urobilin is a metabolic product derived from 
urobilinogen and is primarily excreted through urine, as shown in Figure 6) turned 
positive in germfree animals infected with a single Clostridium-like microorganism 
that had been isolated from the intestinal contents of rats that showed the presence 
of bilins in fecal matter. The bilin output increased in these animals after infection 
Figure 6. 
A depiction of the catabolism of heme into stercobilin. The enterohepatic cycle in which stercobilin can be 
recirculated back and excreted instead through the urine is also shown. The line shows the point in which 
bacterial interaction takes over in the metabolic pathway to create stercobilin.
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with Escherichia coli, although not reaching the levels observed for controls [52]. In 
context, our results showing depleted stercobilin and stercobilinogen in fecal matter 
of ASD model mice might suggest that Clostridium constitutes part of their micro-
biota but that E. coli may have been impacted such that bilin production is reduced. 
Clearly, microbiological testing of fecal matter from ASD model mice is needed 
to provide additional insight. A recent report on microbiota and fecal metabolites 
comparing humans with ASD vs. controls revealed discernible differences between 
the two groups [53]. How this might be applicable to our murine ASD model is a 
subject worthy of follow-up investigation.
Due to the high number of differences observed in the gut microbiome of those 
with ASD [54], it is possible that the bacterial population variations are making an 
important impact on bilin metabolism. The significance of the gut on brain activ-
ity has begun to be heavily researched. In some studies, disorders such as autism, 
depression, and anxiety have seen lessening of symptoms based on the introduction 
of different bacteria within the patient’s microbiome [13]. In particular, the altered 
microbiome of those with ASD has developed changes in the production of short-
chain fatty acids. One such fatty acid noted was propionic acid, which has been 
reported to be increased in those with autism [55]. Activity on propionic acid chains 
are important to the conversion of bilirubin to bilirubin diglucuronide and may 
provide insight into the potential depletion observed [56].
Based on previous knowledge of the production of stercobilin within humans, 
the results presented herein suggest that microbiome analysis coupled to the 
molecular analysis of bilins from fecal material is warranted. Fecal material can be 
collected noninvasively and proved to give a wealth of metabolomic information. 
Through the combination of these techniques, a combinatory biochemical and 
molecular biological approach to diagnosing ASD may yet be developed.
6. Conclusions
The discovery that stercobilin, and to a lesser extent stercobilinogen, are 
depleted in the fecal matter from a murine ASD model gives promise of the 
potential of these substances to serve as clinical biomarkers for ASD. Work to 
understand the relationship between the depletion of these bilins and the identity 
of the microbiota responsible is intriguing, as is the possibility that microbiota 
may play a role in the etiology of ASD; if this is true, it means that fecal trans-
plants may have impact in the treatment of ASD, as recent clinical evidence 
suggests [57].
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